EC905

DRUG5 trials

Sponsors

Astellas Pharma Europe B.V.

Conditions

Benign Prostatic HyperplasiaDrug-Drug Interaction (DDI)EC905HealthyHealthy SubjectsLower Urinary Tract SymptomsMultiple DosePharmacokinetics

Phase 1

A Study to Evaluate Whether Verapamil Has an Effect on the Uptake and Elimination of Solifenacin and Tamsulosin When Administered in a Combination Tablet

CompletedNCT01943487

Astellas Pharma Europe B.V.Drug-Drug Interaction (DDI), Healthy Subjects

Start: 2009-08-31End: 2009-12-31Updated: 2014-05-30

A Study to Evaluate How Tamsulosin (at 1 Dose) and Solifenacin (at 2 Different Doses) Are Taken up From the Intestine, Distributed Through the Body and Eliminated From the Body When Administered in Combination as a Single Tablet (Called EC905)

CompletedNCT01953848

Astellas Pharma Europe B.V.EC905, Healthy Subjects, Multiple Dose +1

Start: 2010-04-30End: 2010-07-31Updated: 2014-05-29

A Study to Evaluate Whether Food Has an Effect on the Uptake of Solifenacin and Tamsulosin When Administered in a Combination Tablet

CompletedNCT01953861

Astellas Pharma Europe B.V.EC905, Healthy Subjects, Pharmacokinetics

Start: 2010-04-30End: 2010-06-30Updated: 2014-05-29

A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin

CompletedNCT01953887

Astellas Pharma Europe B.V.EC905, Healthy Subjects, Pharmacokinetics

Start: 2010-03-31End: 2010-07-31Updated: 2014-05-29

EC905 Pharmacokinetic Profile Study

CompletedNCT02634489

Astellas Pharma Europe B.V.Benign Prostatic Hyperplasia, Healthy, Lower Urinary Tract Symptoms +1

Start: 2009-03-31End: 2009-07-31Updated: 2015-12-18